RxDoctor Payments Data

Santiago Baez-Torres, MD

Cardiovascular Disease · Ponce, PRNPI 1235115825

Payments from drug & device makers

$7,242in general payments, 2019–2025

Across 225 payments — averaging $32.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Medtronic$1K
  • Boston Scientific$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$876
  • Johnson & Johnson$573
  • Abbott$342
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$5047%
  • Food & beverage$6,73893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,242 in reported general payments places this provider in the 75th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,762
Medicare patients
47
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$75,208
XareltoRivaroxaban30$17,361
BrilintaTicagrelor28$13,924
Repatha SyringeEvolocumab20$11,359
FarxigaDapagliflozin Propanediol15$11,111
Omega-3 Acid Ethyl Esters164$9,569
EntrestoSacubitril/Valsartan13$9,032
Repatha SureclickEvolocumab16$8,744
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid65$4,969
Carvedilol612$4,016
Atorvastatin Calcium388$2,935
Candesartan Cilexetil36$2,809
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide107$2,567
Amiodarone Hcl22$2,121
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril167$1,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$75,208125 claims
AstraZenecaBrilinta, Farxiga$321$25,03543 claims
Johnson & JohnsonXarelto$573$17,36130 claims
NovartisEntresto$33$9,03213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →